At the end of the latest market close, Atossa Therapeutics Inc. (ATOS) was valued at $2.32. In that particular session, Stock kicked-off at the price of $2.36 while reaching the peak value of $2.4617 and lowest value recorded on the day was $2.15. The stock current value is $2.33.
Recently in News on April 30, 2021, Atossa Therapeutics CEO Dr. Steven Quay to Participate in Panel Discussion at Cello Health’s Cancer Progress Virtual Conference on May 6, 2021. Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, today announced that Atossa CEO Dr. Steven Quay will participate in a panel discussion at Cello Health’s Cancer Progress Virtual Conference on May 6, 2021 at 10:00 AM ET. The conference will be conducted from May 4-6, 2021. You can read further details here
Atossa Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $4.90 on 02/04/21, with the lowest value was $0.88 for the same time period, recorded on 01/06/21.
Atossa Therapeutics Inc. (ATOS) full year performance was 6.88%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Atossa Therapeutics Inc. shares are logging -54.13% during the 52-week period from high price, and 187.65% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.81 and $5.08.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 15150283 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Atossa Therapeutics Inc. (ATOS) recorded performance in the market was 145.26%, having the revenues showcasing 5.43% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 281.52M, as it employees total of 4 workers.
The Analysts eye on Atossa Therapeutics Inc. (ATOS)
During the last month, 1 analysts gave the Atossa Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.06, with a change in the price was noted +0.85. In a similar fashion, Atossa Therapeutics Inc. posted a movement of +57.43% for the period of last 100 days, recording 18,590,617 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ATOS is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical rundown of Atossa Therapeutics Inc. (ATOS)
Raw Stochastic average of Atossa Therapeutics Inc. in the period of last 50 days is set at 40.09%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 71.43%. In the last 20 days, the company’s Stochastic %K was 72.87% and its Stochastic %D was recorded 71.69%.
Considering, the past performance of Atossa Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 145.26%. Additionally, trading for the stock in the period of the last six months notably improved by 48.41%, alongside a boost of 6.88% for the period of the last 12 months. The shares increased approximately by 31.64% in the 7-day charts and went up by 10.43% in the period of the last 30 days. Common stock shares were driven by 5.43% during last recorded quarter.